HAUPPAUGE, N.Y., July 19, 2023 (Newswire.com) – Botannis Labs NY Inc. is delighted to announce the successful completion of a facility inspection by the U.S. Food and Drug Administration (FDA), the leading regulatory body overseeing the nutraceutical and pharmaceutical industries. The successful inspection validates Botannis’ commitment to delivering exceptional analytical testing services.
This was a routine inspection conducted by the FDA to ensure compliance with quality assurance standards and regulations. Botannis Labs’ facility operations were reviewed including equipment, processes, controls, products, employee practices, and records/documentation. The inspection resulted in zero regulatory violations or objectionable conditions/practices occurring at Botannis Labs.
“We’re extremely happy to announce the conclusion of this routine inspection,” said Matt Wolf, CEO of Botannis Labs. “Botannis has an ongoing commitment to quality assurance and this inspection highlights that our quality management system is compliant with FDA regulations.”
Read full press release here.
###
ABOUT BOTANNIS LABS NY INC.
Botannis is a NY State Licensed, ISO-Certified, cGMP product testing lab that provides a comprehensive scope of harmonized GMP testing services and regulatory consulting. Botannis Labs’ team of experts leverage their decades of experience to utilize optimized testing methods and quality procedures to help assure the compliance of partner brands and the safety of consumers. With modern capabilities and a rigorous dedication to quality, Botannis provides clients access to advanced analysis and cutting-edge laboratory services. Learn more at www.botannis.com.